Hydromorphone-3-glucuronide: biochemical synthesis and preliminary pharmacological evaluation (Q48406950)

11 February 2018

title

Hydromorphone-3-glucuronide: biochemical synthesis and preliminary pharmacological evaluation (English)

1 reference

11 February 2018

1 reference

3

1 reference

11 February 2018

author name string

Wright AW

series ordinal

1

1 reference

11 February 2018

Nocente ML

series ordinal

2

1 reference

11 February 2018

language of work or name

English

0 references

publication date

1 January 1998

1 reference

11 February 2018

published in

Life Sciences

1 reference

11 February 2018

volume

63

1 reference

11 February 2018

issue

5

1 reference

11 February 2018

page(s)

401-411

1 reference

11 February 2018

Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900288-4

Opioid hyperexcitability: the application of alternate opioid therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900288-4

Hydromorphone and metabolite pharmacokinetics in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900288-4

Intravenous methadone for cancer pain unrelieved by morphine and hydromorphone: clinical observations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900288-4

Urinary excretion of hydromorphone and metabolites in humans, rats, dogs, guinea pigs, and rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900288-4

The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900288-4

Biochemical basis for analgesic activity of morphine-6-glucuronide. I. Penetration of morphine-6-glucuronide in the brain of rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900288-4

Morphine derivatives with diminished opiate receptor potency show enhanced central excitatory activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900288-4

High dose of spinal morphine produce a nonopiate receptor-mediated hyperesthesia: clinical and theoretic implications.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900288-4

Morphine-3-glucuronide--a potent antagonist of morphine analgesia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900288-4

The excitatory effects of morphine-3-glucuronide are attenuated by LY274614, a competitive NMDA receptor antagonist, and by midazolam, an agonist at the benzodiazepine site on the GABAA receptor complex.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900288-4

Myoclonus associated with treatment with high doses of morphine: the role of supplemental drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900288-4

Norpethidine induced myoclonus in a patient with renal failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900288-4

Failure of epidural opioid to control cancer pain in a patient previously treated with massive doses of intravenous opioid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900288-4

Myoclonic seizure activity with chronic high-dose spinal opioid administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900288-4

Hyperalgesia and myoclonus with intrathecal infusion of high-dose morphine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900288-4

Putative role of hydromorphone metabolites in myoclonus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900288-4

Clonazepam treatment of myoclonic contractions associated with high-dose opioids: case report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900288-4

Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900288-4

Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900288-4

Hydromorphone metabolite accumulation in renal failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900288-4

Epidural and intravenous opioid-induced neuroexcitation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900288-4

Use of methadone in a highly tolerant patient receiving parenteral hydromorphone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900288-4

Individualized use of methadone and opioid rotation in the comprehensive management of cancer pain associated with poor prognostic indicators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900288-4

Oral morphine in cancer pain: influences on morphine and metabolite concentration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900288-4

Morphine-3-glucuronide: evidence to support its putative role in the development of tolerance to the antinociceptive effects of morphine in the rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900288-4

Quantitation of Morphine, Morphine-3-Glucuronide, and Morphine-6-Glucuronide in Plasma and Cerebrospinal Fluid Using Solid-Phase Extraction and High-Performance Liquid Chromatography with Electrochemical Detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900288-4

Attenuation of hippocampal inhibition by a NMDA (N-methyl-D-aspartate) receptor antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900288-4

Biochemical synthesis, purification and preliminary pharmacological evaluation of normorphine-3-glucuronide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900288-4

Morphine 6-glucuronide and morphine 3-glucuronide as molecular chameleons with unexpected lipophilicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900288-4

Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression in the rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900288-4

Lack of morphine-6-glucuronide antinociception after morphine treatment. Is morphine-3-glucuronide involved?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900288-4

10.1016/S0024-3205(98)00288-4

7 January 2021

Identifiers

DOI

1 reference

11 February 2018

1 reference

11 February 2018